NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday

NextCure (NASDAQ:NXTC) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, analysts expect NextCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NextCure Price Performance

Shares of NXTC opened at $0.72 on Thursday. NextCure has a 1 year low of $0.66 and a 1 year high of $2.57. The company has a market capitalization of $20.17 million, a price-to-earnings ratio of -0.34 and a beta of 0.71. The business has a 50-day moving average of $0.78 and a 200-day moving average of $1.10.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective (down previously from $4.00) on shares of NextCure in a research report on Friday, March 7th.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.